Real-world look at hypertrophic cardiomyopathy in adults in China

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective observational cohort study enrolling adults with hypertrophic cardiomyopathy in China to describe baseline characteristics, treatment patterns, and longitudinal outcomes in routine clinical practice. There are no interventions; data are collected from medical records and patient reports to understand real-world management. The study uses the 2023 guidelines for diagnosis and treatment to identify eligible participants and excludes uncontrolled hypertension and certain valvular diseases. The primary aim is to characterize how patients are managed over time and what outcomes arise in non-trial settings. The lead sponsor is the Second Affiliated Hospital, Zhejiang University School of Medicine, with two participating sites in Hangzhou, China.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Willing and able to provide written informed consent (ICF) and any required privacy authorization before the start of the study.
2. Aged ≥18 years at the time of signing the written informed consent.
3. Diagnosed with hypertrophic cardiomyopathy (HCM) according to the 2023 Guideline for Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy, meeting the following criteria:

   1. Left ventricular wall thickness ≥15 mm in any segment at end-diastole, as assessed by echocardiography or cardiac magnetic resonance imaging (MRI).
   2. Left ventricular wall thickness ≥13 mm in individuals with a positive pathogenic gene test or those identified as members of a genetically affected family.
   3. Exclusion of other cardiovascular diseases or systemic/metabolic diseases causing ventricular wall thickening.

Exclusion Criteria:

1. Uncontrolled primary hypertension.
2. Moderate or severe aortic valve stenosis and/or primary mitral valve disease with severe mitral regurgitation.
3. Confirmed infiltrative or storage diseases with a phenotype resembling hypertrophic cardiomyopathy (e.g., Fabry disease, amyloidosis).
4. Expected life expectancy \<1 years.
5. Severe infections, liver failure, renal failure, or other life-threatening conditions.

Where it's running

• Second Affiliated Hospital, Zhejiang University School of Medicine
  Hangzhou, Zhejiang, China Recruiting
• 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China
  Hangzhou, Zhejiang, China Not yet recruiting

Study contacts

• Principal investigator: Xiaojie Xie, PhD — Second Affiliated Hospital, Zhejiang University, School of Medicine
• Study coordinator: Jianqiang Song, MD
• Email: 22318324@zju.edu.cn
• Phone: +86 15267083207

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Transitioning from mavacamten to aficamten in obstructive HCM

  This study tests whether switching from mavacamten to aficamten is feasible and safe for people with obstructive hypertrophic cardiomyopathy who are already on mavacamten.

  Recruiting Phase 4 Oregon Health and Science University · Kansas City, Missouri and 1 other locations · NCT07600177

• 68Ga-NI-FAPI-04 PET/CT imaging to detect fibroblast activation in cancer, fibrotic, and heart diseases

  This test will see if an injected PET tracer called 68Ga-NI-FAPI-04 can better show fibroblast activation in people with tumors, pulmonary fibrosis, certain autoimmune vascular diseases, hypertrophic cardiomyopathy, or other cardiovascular conditions.

  Recruiting Phase 1/2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07464132

• Understanding why AF happens and is harder to treat in hypertrophic cardiomyopathy

  We’re testing how heart electrical signals and advanced imaging relate to atrial fibrillation in people with hypertrophic cardiomyopathy to see if treatments can be improved.

  Recruiting Guy's and St Thomas' NHS Foundation Trust · London · NCT07454135

• UK multicentre hypertrophic cardiomyopathy registry

  This project collects health information from adults with hypertrophic cardiomyopathy across UK NHS hospitals to see which treatments and tests work best for different patients.

  Recruiting University of Manchester · Manchester · NCT07381894

• Multimodal analysis of heart biopsy samples

  This project will take one extra small heart biopsy during a clinically needed procedure to test whether detailed molecular and immune analyses can find disease-specific signatures in adults with cardiomyopathies, myocarditis, cardiac amyloidosis, or after heart transplant.

  Recruiting University Hospital, Essen · Essen, North Rhine-Westphalia · NCT07359690

• T1 mapping to characterize heart tissue in common heart diseases

  This project tests whether T1 mapping MRI scans, including dye-free native T1, can define normal and disease-specific heart tissue values for adults with various heart conditions.

  Recruiting Chinese Academy of Medical Sciences, Fuwai Hospital · Beijing, Beijing Municipality · NCT07354646

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.